Transgenomic Expects New Cold-PCR License to Extend Mutation-Detection Kit Sensitivity

An expanded license with Dana-Farber Cancer Institute for an offshoot of its Cold-PCR technology allows Transgenomic to develop kits that can detect mutations in common cancer-related genes such as KRAS and P53 directly from blood samples and then analyze the variants using multiple sequencing approaches.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.